Viracta Therapeutics Says Pivotal Cancer Trial Achieves Efficacy Threshold For Expansion Into Next Stage
Portfolio Pulse from Vandana Singh
Viracta Therapeutics Inc (NASDAQ:VIRX) announced that their pivotal NAVAL-1 clinical trial for relapsed or refractory EBV+ peripheral T-cell lymphoma (R/R EBV+ PTCL) has met the pre-specified efficacy threshold for advancement to Stage 2. The decision is based on achieving a predetermined minimum number of objective responses within the first ten enrolled patients. The company's shares are up 5.5% at $1.51.
June 28, 2023 | 4:52 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Viracta Therapeutics' NAVAL-1 clinical trial has met the efficacy threshold for advancement to Stage 2, leading to a 5.5% increase in the company's share price.
The advancement of Viracta's NAVAL-1 clinical trial to Stage 2 indicates positive progress in the company's research and development efforts. This news has been positively received by the market, leading to a 5.5% increase in the company's share price. Given the direct impact of this news on the company's operations and its immediate effect on the stock price, the relevance, importance, and confidence scores are high.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100